Trial Profile
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie; Sumitomo Pharma America
- 12 Feb 2021 Status changed from active, no longer recruiting to completed.
- 15 May 2020 Planned End Date changed from 28 Sep 2021 to 21 Jul 2021.
- 15 May 2020 Planned primary completion date changed from 28 Sep 2021 to 21 Jul 2021.